All Pheast Therapeutics articles
-
ArticleCD24 emerges as the next macrophage checkpoint
With CD47 therapies constrained by safety, attention is turning to CD24 as a macrophage checkpoint target. Pheast’s PHST001 has now entered the clinic.
-
ArticleThe potential of CD24 in cancer immunotherapy
Cofounder & Chief Scientific Officer of Pheast Therapeutics, Dr Roy Maute, reveals his company’s promising drug candidate and explains why they have focused on their chosen target.